Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.

Shares of Esperion Therapeutics Inc. climbed more than 19 percent after the company announced its Phase II combination cholesterol treatment showed tremendous success in lowering low density lipoprotein cholesterol levels in patients.

Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks   TARRYTOWN, N.Y. and PARIS, Sept. 28, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted marketing authorization for Praluent® (alirocumab) for the treatment of bad cholesterol, known as […]